Bristol Myers Squibb (NYSE:BMY) Stock Price Target Raised at Rothschild & Co Redburn

by · The Cerbat Gem

Bristol Myers Squibb (NYSE:BMY – Free Report) had its price target boosted by Rothschild & Co Redburn from $51.00 to $53.00 in a report issued on Thursday. Rothschild & Co Redburn currently has a neutral rating on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on BMY. Roth Capital began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target for the company. Raymond James Financial initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “strong-buy” rating on the stock. Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 5th. Truist Financial reissued a “buy” rating and set a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Citigroup reissued a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $64.96.

Read Our Latest Analysis on BMY

Bristol Myers Squibb Price Performance

NYSE BMY traded down $0.40 during trading hours on Thursday, reaching $59.18. The company’s stock had a trading volume of 6,207,278 shares, compared to its average volume of 11,985,270. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $68.64. The company’s 50-day moving average is $64.27 and its two-hundred day moving average is $60.28. The firm has a market capitalization of $120.89 billion, a price-to-earnings ratio of 13.04, a P/E/G ratio of 0.28 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the prior year, the company posted $1.46 EPS. The business’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts predict that Bristol Myers Squibb will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.05% of the company’s stock.

Institutional Trading of Bristol Myers Squibb

Institutional investors and hedge funds have recently made changes to their positions in the business. Davis Asset Management L.P. purchased a new position in Bristol Myers Squibb during the second quarter valued at $27,000. Addison Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at $32,000. Bayban acquired a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $31,000. Groupe la Francaise increased its holdings in shares of Bristol Myers Squibb by 562.9% in the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 501 shares during the period. Finally, Kilter Group LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth $35,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

  • Positive Sentiment: Positive Phase 3 Zenbexus data: Bristol Myers reported that Zenbexus (iberdomide), combined with daratumumab and dexamethasone, delivered superior progression-free survival versus standard of care in relapsed or refractory multiple myeloma. The EXCALIBER-RRMM results reportedly reduced the risk of progression or death by 51% and produced high minimal residual disease-negative complete response rates, supporting the potential for accelerated approval and future revenue growth. What Could Bristol Myers Squibb Phase 3 Myeloma Data Mean For Investors?
  • Positive Sentiment: Pipeline and commercial support: Coverage highlights Zenbexus as a potential growth driver, while Reblozyl’s expanding sales and additional indications may help offset declines from older products. Investors are also attracted to BMY’s profitability, relatively low valuation and high dividend yield. High-Yield Stocks to Buy in October
  • Neutral Sentiment: Analyst opinions are mixed: J.P. Morgan issued a Buy rating, while Scotiabank maintained a Hold rating. The split suggests that Zenbexus’s clinical progress is encouraging, but investors remain cautious about execution, competition and the company’s longer-term growth outlook. J.P. Morgan Buy Rating
  • Negative Sentiment: Price-target cuts weigh on sentiment: Morgan Stanley assigned a Sell rating, and Cantor Fitzgerald lowered its price target from $59 to $53 while keeping a Neutral rating. These calls indicate concern that the positive pipeline news may already be reflected in the stock or may not fully offset product concentration and competitive risks. Morgan Stanley Sell Rating

About Bristol Myers Squibb

(Get Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.

Further Reading